InMed says Mentari merger to deliver USD 490 million in gross proceeds, restore Nasdaq equity compliance
InMed is set to merge with Mentari Therapeutics under an agreement signed May 19, 2026, subject to shareholder approval. The combined company is expected to receive about USD 490 million in gross proceeds from Mentari’s pre-closing financing, including USD 50 million from convertible notes. The transaction is expected to close in the fourth quarter of 2026. * InMed’s shares closed up about USD 0.68, a 99.8% gain versus the close before the merger agreement was first disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202609181645NEWSFILECNPR____20260918_315023_1) on September 18, 2026, and is solely responsible for the information contained therein. (C)
InMed is set to merge with Mentari Therapeutics under an agreement signed May 19, 2026, subject to shareholder approval. The combined company is expected to receive about USD 490 million in gross proceeds from Mentari’s pre-closing financing, including USD 50 million from convertible notes. The transaction is expected to close in the fourth quarter of 2026. 8% gain versus the close before the merger agreement was first disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref.
ID: 202609181645NEWSFILECNPR____20260918_315023_1) on September 18, 2026, and is solely responsible for the information contained therein. (C)